| Reference number |
2025-00336 |
| Coordinator |
NextCell Pharma AB |
| Funding from Vinnova |
SEK 0 |
| Project duration |
March 2025 - March 2025
|
| Status |
Completed |
| Venture |
Global cooperation 2025 |
Important results from the project
The goal was to increase NextCell´s exposure to international investors. In addition, Swiss Nordic Bio is an excellent event to meet industry colleagues and make new contacts for future collaborations.
Expected long term effects
Developing new treatments requires a long-term approach and resources. It is important to keep investors informed about the business on an ongoing basis. If you choose to take the treatment all the way to patients on your own, a lot of capital is required.
Approach and implementation
Swiss Nordic Bio offers 1-on-1 meetings with specialist investors. An excellent way to get direct contact.
The project description has been provided by the project members themselves and the text has not been looked at by our editors.
